Gamida Cell
Latest round
- Series E
Last raised
- May 2012
Total raised
- $46M
Investors
- 5
About Gamida Cell
Gamida Cell specializes in advanced cell therapy solutions. Founded in 1998 in Jerusalem, Israel, the company has undergone strategic pivots to focus on allogeneic cell therapies. Abigail Jenkins currently serves as the CEO.Gamida Cell specializes in advanced cell and immune therapy technologies, focusing on the development of allogeneic cell therapy products aimed at treating hematologic malignancies. Central to their offerings is Omisirge® (omidubicel-onlv), a proprietary product that utilizes nicotinamide (NAM) technology to enhance and expand cells, ultimately aiming to provide potentially curative treatment options for patients who may not have access to matched allo-HSCT (hematopoietic stem cell transplantation). The company’s technology addresses significant medical needs in the oncology space, particularly for patients experiencing infusion reactions, graft versus host disease, engraftment syndrome, and graft failure.Gamida Cell’s revenue generation is primarily driven through the sale of its specialized cellular therapies, including its flagship product, Omisirge®. The firm engages in direct business transactions with healthcare providers and hospitals, establishing partnerships that facilitate the integration of their therapies into clinical practice. Transactions typically occur on a B2B basis, where healthcare institutions purchase treatment solutions based on patient needs and institutional protocols, often involving negotiated pricing agreements that reflect the value and complexity of the therapies provided. The company is also targeting expansion into new markets, specifically aiming to enhance its presence in Europe and North America by the end of 2023. The funds will assist in facilitating these initiatives and aligning with the strategic goals for growth and market penetration.
Who invested in Gamida Cell
5 investors across 5 rounds
See all investors in Gamida Cell
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Gamida Cell
Who invested in Gamida Cell?
Gamida Cell has 5 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gamida Cell raised?
Gamida Cell has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Gamida Cell last raise money?
Gamida Cell's most recent round on record is a Series E, in May 2012.
What does Gamida Cell do?
Gamida Cell specializes in advanced cell therapy solutions.
Where is Gamida Cell headquartered?
Gamida Cell is headquartered in Jerusalem, Israel.
Which VCs invest in companies like Gamida Cell?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Gamida Cell's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Gamida Cell? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.